Trial · NCT05171075
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
NCT05171075, Phase 3, Terminated, Anthos Therapeutics, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE. Trials, record NCT05171075. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05171075
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
- NCT number
- NCT05171075
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 417 participants, actual
- Lead sponsor
- Anthos Therapeutics, Inc.
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Interventions
- Abelacimab, Dalteparin
- First posted
- 2021-12-28
- Last updated
- 2026-04-17
- Other registries' IDs
- eudract:2021-003085-12
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to first event of centrally adjudicated VTE recurrence | up to 6 months | Time to first adjudicated venous thromboembolism (VTE) event recurrence |
| Secondary | Time to first event of ISTH-adjudicated major or clinically relevant non-major (CRNM) bleeding events | up to 6 months | Time to first adjudicated major or clinically relevant non-major (CRNM) bleeding event |
| Secondary | Time to first event of VTE recurrence, ISTH adjudicated major or ISTH-adjudicated CRNM bleeding events | up to 6 months | Time to first adjudicated venous thromboembolism (VTE) or bleeding event |
| Secondary | Time to event of permanent treatment discontinuation not due to death | up to 6 months | Time to permanent discontinuation not due to death |
| Secondary | Time to first event of ISTH-adjudicated CRNM bleeding events | up to 6 months | Time to first adjudicated clinically relevant non-major (CRNM) bleeding event |
| Secondary | Time to first event of ISTH-adjudicated major bleeding events | Up to 6 months | Time to first adjudicated major bleeding event |
| Secondary | Time to first event of GI ISTH-adjudicated major and GI CRNM bleeding events | up to 6 months | Time to first adjudicated gastrointestinal (GI) major and clinically relevant non-major (CRNM) bleeding event |
| Secondary | All-cause death, vascular death, serious adverse events, adverse events leading to drug discontinuation, other adverse events, abnormal lab tests, etc. presented as rate per 100 patient-years | up to 6 months | |
| Secondary | For patients treated with abelacimab: percent with injection site reactions/severity, hypersensitivity reactions/severity, anti-drug antibody formation, neutralizing antibody | up to 6 months |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05171075
GET https://conductscience.org/api/trials/v1/NCT05171075/registered